Related references
Note: Only part of the references are listed.A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy
Zaoqu Liu et al.
FRONTIERS IN IMMUNOLOGY (2022)
Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
Shun-Long Ou et al.
FRONTIERS IN IMMUNOLOGY (2022)
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Michael Boyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Tislelizumab uniquely binds to the CC′ loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage
Yuan Hong et al.
FEBS OPEN BIO (2021)
Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors
Xiaozheng Xu et al.
ELIFE (2021)
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Xin Cai et al.
FRONTIERS IN GENETICS (2021)
PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment
Tomohiro Takehara et al.
COMMUNICATIONS BIOLOGY (2021)
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies
Richard Copin et al.
CELL (2021)
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
Alina Baum et al.
SCIENCE (2020)
Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
Xiaoying Sun et al.
BMC CANCER (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups
Lawrence P. Andrews et al.
NATURE IMMUNOLOGY (2019)
Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
Annika De Sousa Linhares et al.
SCIENTIFIC REPORTS (2019)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Not All Immune Checkpoints Are Created Equal
Annika De Sousa Linhares et al.
FRONTIERS IN IMMUNOLOGY (2018)
Immuno-Oncology: Emerging Targets and Combination Therapies
Henry T. Marshall et al.
FRONTIERS IN ONCOLOGY (2018)
Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature
Rathi N. Pillai et al.
CANCER (2018)
Introduction to checkpoint inhibitors and cancer immunotherapy INTRODUCTION
Arlene H. Sharpe
IMMUNOLOGICAL REVIEWS (2017)
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
Krzysztof M. Zak et al.
STRUCTURE (2017)
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Hyun Tae Lee et al.
SCIENTIFIC REPORTS (2017)
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer
Monica Khunger et al.
CHEST (2017)
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Jennifer H. Yearley et al.
CLINICAL CANCER RESEARCH (2017)
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H. Baumeister et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju Yeon Lee et al.
NATURE COMMUNICATIONS (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Expanded palette of Nano-lanterns for real-time multicolor luminescence imaging
Akira Takai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators
Isabelle Le Mercier et al.
FRONTIERS IN IMMUNOLOGY (2015)
The Immunological Synapse: A Molecular Machine Controlling T Cell Activation
Arash Grakoui et al.
JOURNAL OF IMMUNOLOGY (2015)
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Xiangguo Qiu et al.
NATURE (2014)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Tadashi Yokosuka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo
Shunsuke Chikuma et al.
JOURNAL OF IMMUNOLOGY (2009)
Spatiotemporal Regulation of T Cell Costimulation by TCR-CD28 Microclusters and Protein Kinase C θ Translocation
Tadashi Yokosuka et al.
IMMUNITY (2008)
Immunological synapse and microclusters: the site for recognition and activation of T cells
Takashi Saito et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
Newly generated T cell receptor microclusters initiate and sustain T cell activation by recruitment of Zap70 and SLP-76
T Yokosuka et al.
NATURE IMMUNOLOGY (2005)
Actin and agonist MHC-peptide complex-dependent T cell receptor microclusters as scaffolds for signaling
G Campi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ
KA Sheppard et al.
FEBS LETTERS (2004)
The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role
P Youngnak-Piboonratanakit et al.
IMMUNOLOGY LETTERS (2004)
T cell receptor ligation induces the formation of dynamically regulated signaling assemblies
SC Bunnell et al.
JOURNAL OF CELL BIOLOGY (2002)
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
T Okazaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
SY Tseng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
